- Home
- MIRM vs NAVN Comparison
MIRM vs NAVN Comparison
Compare MIRM & NAVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | NAVN |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.0B |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MIRM | NAVN |
|---|---|---|
| Price | $84.87 | $27.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $153.43 | $30.80 |
| AVG Volume (30 Days) | 696.6K | ★ 2.4M |
| Earning Date | 11-10-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,138,000.00 | ★ $702,265,000.00 |
| Revenue This Year | $33.91 | $32.58 |
| Revenue Next Year | $17.40 | $24.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.82 |
| 52 Week Low | $63.23 | $8.11 |
| 52 Week High | $130.00 | $30.88 |
Technical Indicators
Market Signals| Indicator | MIRM | NAVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 65.58 |
| Support Level | $78.07 | $18.53 |
| Resistance Level | $88.31 | $28.08 |
| Average True Range (ATR) | 3.72 | 0.95 |
| MACD | 0.80 | 0.44 |
| Stochastic Oscillator | 66.21 | 88.29 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About NAVN Navan Inc.
Navan Inc is engaged in providing an end-to-end, AI-powered software platform for managing business travel and expense (T&E). The company's platform enables users to manage corporate travel bookings, payments, and expense processes, while providing tools for customers to control and optimize spending and for suppliers to access demand. Geographically, the company operates in the United States, the United Kingdom, and other countries, with the majority of its revenue generated from the United States.